Kezar Life Sciences, Inc. (KZR) Cash from Financing Activities (2017 - 2026)

Kezar Life Sciences has reported Cash from Financing Activities for 10 years, with the latest figure at $267000.0 in Q1 2026.

• Quarterly Cash from Financing Activities rose 120.48% year-over-year to $267000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.0 million (down 650.54% YoY) and the FY2025 annual result came in at -$10.6 million, down 10376.7% from the prior year.
• Cash from Financing Activities rose to $267000.0 in Q1 2026 per KZR's latest filing, from -$6.7 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $78.3 million in Q2 2022 and troughed at -$6.7 million in Q4 2025.
• A 5-year average of $7.9 million and a median of $59000.0 in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities surged 27673.76% in 2022, then plunged 14370.21% in 2025.
• Over 5 years, Cash from Financing Activities stood at $506000.0 in 2022, then sank by 88.34% to $59000.0 in 2023, then dropped by 20.34% to $47000.0 in 2024, then slumped by 14370.21% to -$6.7 million in 2025, then soared by 103.98% to $267000.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $267000.0, -$6.7 million, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.